#VisualAbstract: Sodium–Glucose Co-Transporter-2 (SGLT2) Inhibitors Do Not Improve Survival Free of Organ Support in COVID-19
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: sglt2 inhibitors
#VisualAbstract: SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout
In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those ...
Empagliflozin use is associated with slower progression of chronic kidney disease
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...
Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease
1. Dapagliflozin reduced the risk of hospitalization in patients with chronic kidney disease (CKD) with and without type 2 diabetes ...
SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective
1. For sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists to be used as first-line agents for type ...
Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes associated with reduced atrial fibrillation hospitalization events compared to commonly used comparators
1. This population-based cohort study demonstrated that among older adults with type 2 diabetes, sodium-glucose cotransporter-2 inhibitor (SGLT-2i) use was ...
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...
Use of sodium-glucose transport protein 2 inhibitors associated with lowered incidence of gout in patients with type 2 diabetes
1. The use of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes was associated with a lowered ...
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...